CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 99 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $188,255 | -29.9% | 145,934 | -6.5% | 0.00% | 0.0% |
Q2 2023 | $268,389 | +32.3% | 156,040 | +16.2% | 0.00% | 0.0% |
Q1 2023 | $202,807 | -16.1% | 134,309 | -11.1% | 0.00% | 0.0% |
Q4 2022 | $241,632 | -21.0% | 151,020 | -28.3% | 0.00% | -50.0% |
Q3 2022 | $306,000 | -19.3% | 210,699 | +1.8% | 0.00% | 0.0% |
Q2 2022 | $379,000 | -29.2% | 207,071 | +3.4% | 0.00% | -33.3% |
Q1 2022 | $535,000 | -38.8% | 200,199 | -0.8% | 0.00% | -25.0% |
Q4 2021 | $874,000 | +212.1% | 201,758 | +267.2% | 0.00% | +300.0% |
Q3 2021 | $280,000 | -60.7% | 54,945 | -40.4% | 0.00% | -75.0% |
Q1 2021 | $713,000 | +86.2% | 92,243 | +57.7% | 0.00% | +100.0% |
Q4 2020 | $383,000 | +145.5% | 58,479 | +150.0% | 0.00% | +100.0% |
Q3 2020 | $156,000 | -60.6% | 23,387 | -50.8% | 0.00% | -66.7% |
Q2 2020 | $396,000 | -48.1% | 47,554 | -52.2% | 0.00% | -57.1% |
Q1 2020 | $763,000 | +198.0% | 99,448 | +223.1% | 0.01% | +250.0% |
Q4 2019 | $256,000 | +14.3% | 30,775 | +113.0% | 0.00% | +100.0% |
Q2 2017 | $224,000 | – | 14,450 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |